Safety of hormone replacement therapy in gynaecological cancer survivors

References

• Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL . 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics 72:1117–1130.
   PubMed Web of Science ®Google Scholar
• Ayhan A, Taskiran C, Simsek S, Sever A. 2006. Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? International Journal of Gynecological Cancer 16: 805–808.
   PubMedGoogle Scholar
• Barakat RR, Brundy BN, Spirtos NM, Bell J, Mannel RS. 2006. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynaecologic Oncology Group study. Journal of Clinical Oncology 24:587–592.
   PubMed Web of Science ®Google Scholar
• Beral V. 2007. Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369: 1703–10.
   PubMed Web of Science ®Google Scholar
• Beresford SAA, Weiss NS, Voigt LF, McKnight B. 1997. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349:458–461.
   PubMed Web of Science ®Google Scholar
• Berek JS, editor. 2002. Ovarian cancer. In: Novak's gynecology. 3rd ed. Philadelphia: Lippincott Williams and Wilkins. p 1280–1281.
   Google Scholar
• Bolton JL, Thatcher GR. 2001. Potential mechanisms of estrogen quinine carcinogenesis. Chemical Research in Toxicology 2:93–101.
   Google Scholar
• Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. 1996. Estrogen replacement in surgical stage I and II endometrial cancer survivors. American Journal of Obstetrics and Gynecology 175: 1195–1200.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D . 2003. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. Journal of American Medical Association 289:3243–3253.
   PubMed Web of Science ®Google Scholar
• Coughlin SS, Giustozzi A, Smith SJ, Lee NC. 2000. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. Journal of Clinical Epidemiology 53:367–375.
   PubMed Web of Science ®Google Scholar
• Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. 1986. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstetrics and Gynecology 67:326–330.
   PubMed Web of Science ®Google Scholar
• DiSaia PJ, Creasman WT, editors. 2002. Adenocarcinoma of the uterus. In: Clinical gynecologic oncology. 6th ed. Philadelphia: Mosby. p 137–171.
   Google Scholar
• Eeles RA, Tan S, Wiltshaw E, Fryatt I, A'Hern RP, Shepherd JH . 1991. Hormone replacement therapy and survival after surgery for ovarian cancer. British Medical Journal 302:259–262.
   PubMed Web of Science ®Google Scholar
• Gallup DG, Stock RJ. 1984. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstetrics and Gynecology 64:417–420.
   PubMed Web of Science ®Google Scholar
• Garg PP, Kerlikowske K, Subak L, Grady D. 1998. Hormone replacement therapy and the risk of epithelial ovarian cancer: a meta-analysis. Obstetrics and Gynecology 92:472–479.
   PubMed Web of Science ®Google Scholar
• Guidozzi F, Daponte A. 1999. Estrogen replacement therapy for ovarian carcinoma survivors: a randomised control trial. Cancer 86:1013–1018.
   PubMed Web of Science ®Google Scholar
• Hancke K, Foeldi M, Zahradnik HP, Gitsch G, Gilbert L, Denschlag D. 2010. Climacteric 13:271–277.
   PubMed Web of Science ®Google Scholar
• Hill DA, Weiss NS, Beresford SA, Voigt LF, Daling JR, Stanford JL . 2000. Continuous combined hormone replacement therapy and risk of endometrial cancer. American Journal of Obstetrics and Gynecology 183:1456–1461.
   PubMed Web of Science ®Google Scholar
• Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N ., editors. 2009. SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD. Based on November 2008 SEER data submission, posted to the SEER website. Available at: http://seer.cancer.gov/csr/1975_2006/results_merged/sect_05_cervix_uteri.pdf
   Google Scholar
• King MC, Marks JH, Mandell JB. 2003. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646.
   PubMed Web of Science ®Google Scholar
• Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P . 2006. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecologic Oncology 100:83–88.
   PubMedGoogle Scholar
• Lacey JV Jr, Brinton LA, Barnes WA, Gravitt PE, Greenberg MD, Hadjimichael OC . 2000. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecologic Oncology 77:149–154.
   PubMed Web of Science ®Google Scholar
• Lacey JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P . 2002. Menopausal hormone replacement therapy and risk of ovarian cancer. Journal of American Medical Association 288:334–341.
   PubMed Web of Science ®Google Scholar
• Lee RB, Burke TW, Park RC. 1990. Estrogen replacement therapy following treatment for stage 1 endometrial carcinoma. Gynecologic Oncology 36:189–191.
   PubMed Web of Science ®Google Scholar
• MacLennan AH, Lester S, Moore V. 2001. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 4:58–74.
   PubMedGoogle Scholar
• Mascarenhas C, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I . 2006. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. International Journal of Cancer 119:2907–2915.
   PubMed Web of Science ®Google Scholar
• Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O. 2009. Hormone therapy and ovarian cancer. Journal of American Medical Association 302:298–305.
   PubMed Web of Science ®Google Scholar
• Parker H, Broder M, Chang U, Feskanich D, Farquhar C, Liu Z . 2009. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstetrics and Gynecology 113:1027–1037.
   PubMed Web of Science ®Google Scholar
• Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC . 1997. Estrogen-progestin replacement therapy and endometrial cancer. Journal of National Cancer Institute 89:1110–1116.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Stovall DW, Kightlinger RS 2009. Advances in the treatment of menopausal symptoms. Women's Health (London, England) 5:361–384.
   PubMedGoogle Scholar
• Ploch E. 1987. Hormone replacement therapy in patients after cervical cancer treatment. Gynecologic Oncology 26:169–177.
   PubMed Web of Science ®Google Scholar
• Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. 2001. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. Journal of American Medical Association 285: 1460–1465.
   PubMed Web of Science ®Google Scholar
• Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M . 2003. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361:1159–1167.
   PubMed Web of Science ®Google Scholar
• Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ. 2001. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstetrics and Gynecology 97:555–560.
   PubMed Web of Science ®Google Scholar
• Tangir J, Zelterman D, Ma W, Schwartz PE. 2003. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstetrics and Gynecology 101:251–257.
   PubMed Web of Science ®Google Scholar
• Ursic-Vrscaj M, Bebar S, Zakelj MP. 2001. Hormone replacement therapy after invasive ovarian cystadenocarcinoma treatment: the effect on survival. Menopause 8:70–75.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, PHS. 2005. National toxicology report on carcinogens. 11th ed. Washington: US Department of Health and Human Services.
   Google Scholar
• Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R, Lindgren A . 1999. Risk of endometrial cancer following estrogen replacement therapy with and without progestins. Journal of National Cancer Institute 91:1131–1137.
   PubMed Web of Science ®Google Scholar
• Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. 2006. New England Journal of Medicine 354:270–282.
   PubMed Web of Science ®Google Scholar
• Zalel Y, Piura B, Elchalal U, Czernobilsky B, Antebi S, Dgani R. 1996. Diagnosis and management of malignant germ cell ovarian tumors in young females. International Journal of Gynaecology and Obstetrics 55:1–10.
   PubMedGoogle Scholar